Zevalin (Ibritumomab Tiuxetan) patient information - prescription drugs and medications at RxList

Find a Drug Advanced Search

Professional

Zevalin

Patient Information

font size

Advise patients:

To contact a healthcare professional for severe signs and symptoms of infusion reactions
To take premedications as prescribed [see WARNINGS and PRECAUTIONS].
To report any signs or symptoms of cytopenias (bleeding, easy bruising, petechiae or purpura, pallor, weakness or fatigue)
To avoid medications that interfere with platelet function, except as directed by a healthcare professional [see WARNINGS and PRECAUTIONS].
To seek prompt medical evaluation for diffuse rash, bullae, or desquamation of the skin or oral mucosa
To immediately report symptoms of infection (e.g. pyrexia).[see ADVERSE REACTIONS].
That immunization with live viral vaccines is not recommended for 12 months following the Zevalin therapeutic regimen. [see WARNINGS and PRECAUTIONS].
To use effective contraceptive methods during treatment and for a minimum of 12 months following Zevalin therapy
To discontinue nursing during and after Zevalin treatment. [see Use In Special Populations].